WALVAX(SZ:300142) synbio新材料·2026-02-24 06:00Core Viewpoint - Watson Bio announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund in collaboration with several partners, focusing on synthetic biology and biotechnology sectors [2][5]. Group 1: Fund Details - The target scale of the fund is 1 billion RMB, with Watson Bio contributing 450 million RMB as a limited partner [3]. - The partners and their contributions are as follows: - Guotou Chuangyi Industrial Fund Management Co., Ltd.: 1 million RMB (0.10%) - Central Enterprise Rural Industry Investment Fund Co., Ltd.: 299 million RMB (29.90%) - Yunnan Watson Biotechnology Co., Ltd.: 450 million RMB (45.00%) - Yuxi State-owned Capital Operation Co., Ltd.: 250 million RMB (25.00%) [4]. - The capital will be contributed in three phases: 300 million RMB for the first phase, 300 million RMB for the second phase, and 400 million RMB for the third phase [4]. Group 2: Investment Focus - The fund's core investment direction focuses on synthetic biology, biological manufacturing, and related biotechnology industries [5]. - Specific investment areas include but are not limited to: - Synthetic biology (enzyme preparations, amino acids, probiotics) - Life and health (plant extracts, recombinant collagen, sweeteners, protein drugs) - Biological agriculture (feed protein, micro-ecological preparations, animal vaccines, biological nitrogen fixation) - Bioenergy (bioethanol, biodiesel) - Biomaterials (PLA, PHA, PDO) - Technology platform enterprises (strain development, AI protein design) - High-throughput equipment (microfluidic devices, gene sequencing equipment) [5].